NEW YORK, June 8, 2011 /PRNewswire/ — According to a report
published today by Thomson CompuMark, part of Thomson Reuters, the
pharmaceutical industry has begun to adapt to stricter governmental
brand name standards globally by rapidly increasing the number of
trademarks it files for every new drug. These newer standards by
the U.S. Food and Drug Administration (FDA) and European Medicines
Agency (EMA) are part of an effort to prevent
look-alike/sound-alike pharmaceutical brand names and have led to
increased rejection rates of new drug names.
The special report, Pharmaceutical Trademarks: How to Survive
the Name Game – New Challenges and Opportunities for
Pharmaceutical Companies, tracks trends in pharmaceutical
trademark activity over the last 30 years, incorporates input from
leading trademark attorneys and pharmaceutical industry executives
and analyzes trademark initiatives at the FDA and EMA to shed light
on this critical issue. Following are some of the key observations
in the analysis:
- FDA and EMA Rejection Rates Up: The long-term FDA
trademark rejection rate is 30%, but it has increased to
approximately 36% in recent years as the organization has adopted a
more stringent approach to brand approvals. Combined, the FDA and
EMA are rejecting 40%-50% of pharmaceutical trademarks each
year.
- More than 300% Increase in Global Pharma Trademark
Filings: Between 1980 and 2010, the number of pharmaceutical
trademarks filed increased by more than 300%. A total of 238,010
pharmaceutical trademarks were filed globally in 2010.
- China Filing Most Pharmaceutical Trademarks in 2010:
Chinese firms filed 36,105 pharmaceutical trademarks in 2010, more
than any other region globally. China was followed by the US
(27,545) and India (26,123). Some surprise emerging markets such as
Vietnam, V‘/>”/>
